Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Gross-Profit-to-Asset % : -0.65% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Great Novel Therapeutics Biotech & Medicals's annualized Gross Profit for the quarter that ended in Dec. 2023 was NT$-4.29 Mil. Great Novel Therapeutics Biotech & Medicals's average Total Assets over the quarter that ended in Dec. 2023 was NT$665.50 Mil. Therefore, Great Novel Therapeutics Biotech & Medicals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was -0.65%.

Great Novel Therapeutics Biotech & Medicals Gross-Profit-to-Asset % Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Gross-Profit-to-Asset % Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.16

0.15

0.51

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					0.12	0.42	-	1.80	-0.65

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset % falls into.

Great Novel Therapeutics Biotech & Medicals Gross-Profit-to-Asset % Calculation

Great Novel Therapeutics Biotech & Medicals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	2.615	/	( (372.847	+	644.849)	/ 2 )
	=	2.615	/	508.848
	=	0.51 %

Great Novel Therapeutics Biotech & Medicals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-4.294	/	( (686.152	+	644.849)	/ 2 )
	=	-4.294	/	665.5005
	=	-0.65 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Great Novel Therapeutics Biotech & Medicals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines